

Accepted Manuscript


Title: Targeted gene panel screening is an effective tool to identify undiagnosed late onset pompe disease

Author: Marco Savarese, Annalaura Torella, Olimpia Musumeci, Corrado Angelini, Guja Astrea, Luca Bello, Claudio Bruno, Giacomo Pietro Comi, Giuseppina di Fruscio, Giulio Piluso, Giuseppe Di Iorio, Manuela Ergoli, Gaia Esposito, Marina Fanin, Olimpia Farina, Chiara Fiorillo, Arcomaria Garofalo, Teresa Giugliano, Francesca Magri, Carlo Minetti, Maurizio Moggio, Luigia Passamano, Elena Pegoraro, Ester Picillo, Simone Sampaolo, Filippo Maria Santorelli, Claudio Semplicini, Bjarne Udd, Antonio Toscano, Luisa Politano, Vincenzo Nigro

PII: S0960-8966(17)31489-X
DOI: <https://doi.org/10.1016/j.nmd.2018.03.011>
Reference: NMD 3534

To appear in: *Neuromuscular Disorders*

Received date: 4-12-2017
Accepted date: 29-3-2018



Please cite this article as: Marco Savarese, Annalaura Torella, Olimpia Musumeci, Corrado Angelini, Guja Astrea, Luca Bello, Claudio Bruno, Giacomo Pietro Comi, Giuseppina di Fruscio, Giulio Piluso, Giuseppe Di Iorio, Manuela Ergoli, Gaia Esposito, Marina Fanin, Olimpia Farina, Chiara Fiorillo, Arcomaria Garofalo, Teresa Giugliano, Francesca Magri, Carlo Minetti, Maurizio Moggio, Luigia Passamano, Elena Pegoraro, Ester Picillo, Simone Sampaolo, Filippo Maria Santorelli, Claudio Semplicini, Bjarne Udd, Antonio Toscano, Luisa Politano, Vincenzo Nigro, Targeted gene panel screening is an effective tool to identify undiagnosed late onset pompe disease, *Neuromuscular Disorders* (2018), <https://doi.org/10.1016/j.nmd.2018.03.011>.

This is a PDF file of an unedited manuscript that has been accepted for publication. As a service to our customers we are providing this early version of the manuscript. The manuscript will undergo copyediting, typesetting, and review of the resulting proof before it is published in its final form. Please note that during the production process errors may be discovered which could affect the content, and all legal disclaimers that apply to the journal pertain.

Targeted gene panel screening is an effective tool to identify undiagnosed Late onset Pompe disease

Marco Savarese^{1,2}, Annalaura Torella^{2,3}, Olimpia Musumeci⁴, Corrado Angelini⁵, Guja Astrea⁶, Luca Bello⁷, Claudio Bruno⁸, Giacomo Pietro Comi⁹, Giuseppina di Fruscio², Giulio Piluso², Giuseppe Di Iorio¹⁰, Manuela Ergoli¹¹, Gaia Esposito², Marina Fanin⁷, Olimpia Farina¹⁰, Chiara Fiorillo⁸, Arcomaria Garofalo², Teresa Giugliano², Francesca Magri⁹, Carlo Minetti⁸, Maurizio Moggio¹², Luigia Passamano¹¹, Elena Pegoraro⁷, Ester Picillo¹¹, Simone Sampaolo¹⁰, Filippo Maria Santorelli⁶, Claudio Semplicini⁷, Bjarne Udd^{1,13}, Antonio Toscano⁴, Luisa Politano^{11*}, Vincenzo Nigro^{2,3}

1 Folkhälsan Research Center, Medicum, University of Helsinki, Helsinki, Finland;

2 Dipartimento di Medicina di Precisione, Università degli Studi della Campania “Luigi Vanvitelli”, Napoli, Italy;

3 Telethon Institute of Genetics and Medicine (TIGEM), Pozzuoli, Italy

4 Department of Clinical and Experimental Medicine, University of Messina, Italy;

5 Fondazione Hospital S.Camillo IRCCS, Venezia, Italy;

6 Medicina Molecolare, IRCCS Fondazione Stella Maris, Pisa, Italy;

7 Dipartimento di Neuroscienze, Università di Padova, Padova, Italy;

8 Center of Myology and Neurodegenerative Disease, Istituto Giannina Gaslini, Genova, Italy;

9 Centro Dino Ferrari, Dipartimento di Fisiopatologia Medico-Chirurgica e dei Trapianti, Università degli Studi di Milano, Fondazione IRCCS Ca' Granda, Ospedale Maggiore Policlinico, Milan, Italy

10 Neurology Clinic II and Reference Center for Rare Neuromuscular Disorders, Department of Medical Sciences, Surgery, Neurology, Metabolic Diseases and Geriatrics, Università degli Studi della Campania “Luigi Vanvitelli”, Napoli, Italy;

11 Dipartimento di Medicina Sperimentale, Cardiomiologia e Genetica Medica, Università degli Studi della Campania “Luigi Vanvitelli”, Napoli, Italy;

12 Neuromuscular and Rare Disease Unit, Dipartimento di Neuroscienze, Università degli Studi di Milano, Fondazione IRCCS Ca' Granda, Ospedale Maggiore Policlinico, Milano, Italy;

13 Neuromuscular Research Center, University of Tampere and Tampere University Hospital, Tampere, Finland.

***Corresponding author:**

Prof.ssa Luisa Politano

Cardiomiologia e Genetica Medica, Dipartimento di Medicina Sperimentale, Università degli Studi della Campania “Luigi Vanvitelli”

E-mail: luisa.politano@unicampania.it

Highlights

- The diagnosis of late onset Pompe disease (LOPD) is challenging
- LOPD was identified in 3.47% of high-risk patients
- Several factors can hamper an early diagnosis of LOPD
- Comprehensive gene panels are needed for the screening of myopathy patients.

Abstract

Mutations in the *GAA* gene may cause a late onset Pompe disease presenting with proximal weakness without the characteristic muscle pathology, and therefore a test for *GAA* activity is the first tier analysis in all undiagnosed patients with hyperCKemia and/or limb-girdle muscular weakness.

By using MotorPlex, a targeted gene panel for next generation sequencing, we analyzed *GAA* and other muscle disease-genes in a large cohort of undiagnosed patients with suspected inherited skeletal muscle disorders (n=504). In this cohort, 275 patients presented with limb-girdle phenotype and/or an isolated hyperCKemia.

Mutational analysis identified *GAA* mutations in ten patients. Further seven affected relatives were identified by segregation studies. All the patients carried the common *GAA* mutation c.-32-13T>G and a second, previously reported mutation.

In the subcohort of 275 patients with proximal muscle weakness and/or hyperCKemia, we identified late-onset Pompe disease in 3.47%. The clinical overlap between Pompe disease and LGMDs or other skeletal muscle disorders suggests that *GAA* and the genes causing a metabolic myopathy should be analyzed in all the gene panels used for testing neuromuscular patients. However, enzymatic tests are essential for the interpretation and validation of genetic results.

Keywords: *GAA*, late onset Pompe disease (LOPD), metabolic myopathies, LGMD, hyperCKemia, gene panels

Introduction

Glycogen storage disease II or Pompe disease (MIM 232300) is an autosomal recessive disorder caused by mutations in the *GAA* gene (MIM 606800), encoding alpha-1,4-glucosidase, a lysosomal enzyme involved in the degradation of glycogen (1, 2).

Depending on the level of residual enzymatic activity, mutations in *GAA* lead to a wide spectrum of clinical phenotypes, ranging from a severe infantile form, presenting with cardiomyopathy and muscular hypotonia, to a relatively milder, late onset form of Pompe disease (LOPD), characterized by a slowly progressive proximal muscle weakness, often involving the respiratory muscles (3-5).

The diagnosis of LOPD is challenging and usually achieved with significant delay. LOPD patients, in fact, may exhibit a mild phenotype, partially overlapping that of other neuromuscular disorders (NMDs) (2, 6). Moreover, the histopathological findings are often unspecific, given the fact that often nor glycogen storage or vacuoles are present in LOPD muscle biopsies (7, 8). The clinical overlap with other disorders and the misleading histological features often hamper an early diagnosis at onset of the symptoms, resulting in a diagnostic odyssey (6, 8).

The measurement of *GAA* activity, usually on a dried blood spot (DBS), serves as diagnostic screening test (9), although the results must be confirmed by a second biochemical assay on different tissues as skeletal muscle, fibroblasts or leucocytes and corroborated by the presence of two *GAA* pathogenic mutations (10, 11).

A disease-specific treatment, the enzyme replacement therapy (ERT), is available since 2006.

However, ERT has a limited effect on LOPD patients (12). Early diagnosis and the subsequent early initiation of therapy may have an impact on the therapeutic success, preventing severe muscular and respiratory impairment (6).

In recent years, the development of cutting-edge technologies has revolutionized the diagnostic approach to the genetic disorders (13). Different NGS approaches for the diagnosis of patients with

skeletal muscle diseases have been described in literature (14). In particular, targeted resequencing (TGS) of specific genes of interest represents a cost-effective strategy for the clinical diagnostics of heterogeneous disorders (14, 15).

In this manuscript, we describe clinical and morphological data of 16 LOPD patients identified by performing MotorPlex, an NGS-based platform to analyze genes associated with skeletal muscle disorders, with subsequent segregation analysis in a large cohort of myopathy patients.

Accepted Manuscript

Materials and methods

DNA samples from 504 patients with a broad range of myopathies, including LGMDs, congenital myopathies, distal myopathies, isolated hyperCKemia, were recruited in the network of the Italian Association of Myology. Patients were clinically evaluated by neurologists within tertiary care centers for neuromuscular disorders and had remained without final diagnosis. For each patient, clinical history and laboratory data was collected in a specific form. Patients signed a written informed consent at the time of blood collection. The study was approved by the Ethics Committee of Università degli Studi della Campania “Luigi Vanvitelli” and was performed according to the Declaration of Helsinki.

Genomic DNA was extracted from peripheral blood by phenol/chloroform extraction. All the samples were enriched using MotorPlex (16, 17), a custom assay to analyze a panel of genes causing neuromuscular disorders. All the enrichments were performed according to manufacturer’s instructions (Agilent Technologies, Santa Clara, CA, USA). Each library was run on a HiSeq 1000 (Illumina).

An in-house pipeline (18) was used to analyze the raw sequencing data generated. All the variants were confirmed by Sanger sequencing using an ABI PRISM 3130 XL automatic DNA Sequencer Genetic Analyzer (Applied Biosystems, Foster City, CA, USA).

A segregation analysis was performed according to the availability of DNA from relatives.

A biochemical test evaluating the GAA activity was performed, when possible, on samples from patients with GAA mutations. GAA activity in skeletal muscle, DBS and lymphocytes was assessed by a fluorometric method using the substrate 4-methylumbelliferyl- α -D-glucoside (19). The newly diagnosed LOPD patients were re-assessed, re-evaluating the clinical presentation, functional measures (6 minute walking test, 6MWT), creatine kinase levels and respiratory functions (forced vital capacity, FVC, in supine and/or seated position).

We performed a copy number variant (CNV) analysis by using a custom array-CGH, MotorChip (20) (Agilent Technologies).

Results

Sixteen patients from nine unrelated families were diagnosed with LOPD (patient II has been extensively described elsewhere (21)). All patients showed the common c.-32-13T>G variant (22) and a second, already reported, mutation on the other allele (23-27) (Table 1). In particular, the second allele carried a missense change in seven families and a nonsense variant in the remaining two families. Among LOPD patients, there were more men (10/16, 62.5%) than women (6/16, 37.5%), with a male to female sex ratio of 1.66. Adult onset was observed in almost all patients (13/16, 81.2%), except patients V,1 and VII who showed their first symptoms during adolescence and patient V,3 who had a childhood onset.

The symptoms at onset were mainly proximal weakness (12/16, 75%), and fatigability (10/16, 62.5%). Exercise intolerance, myalgia and contractures were less common in this cohort; some of the patients showed dysphagia. None of the patients had central nervous system involvement at onset; the heart was affected in only one patient with an early adult presentation. Respiratory involvement was observed during the first visit in six patients (37.5%). Increased creatine kinase levels (2.5-10x the upper normal limit) were observed in 14 patients. When performed (6 cases), electromyography showed a myopathic pattern. Muscle biopsy, performed in 9 patients, showed presence of vacuoles in only four patients.

The mean age of the patients was 50.8 ± 11.7 years (range 33-71). The average diagnostic delay was 21.5 years (range=11-38). Two patients used a wheelchair at the time of latest evaluation. GAA enzymatic activity, tested in 11 patients (9 through DBS, 1 each in muscle and lymphocytes) was reduced in all samples, confirming the diagnosis of LOPD.

A marked inter- and intrafamilial phenotypic variability was observed. The presence of a nonsense variant (families VI and IIX) *in trans* with the common c.-32-13T>G variant did not correlate with either a more severe phenotype or an earlier onset of the disease.

Our screening also identified five patients (three affected by LGMD and two by a congenital myopathy), carrying the c.-32-13T>G variant in heterozygosity. In two of them the identification of already described mutations addressed the diagnosis towards a different disease (LGMD2C and nemaline myopathy 1). In the three remaining patients, no other causative variants in *GAA* were identified and a custom array-CGH (20) excluded the presence of any copy number variants affecting this gene in two of them (the third patient was not tested because of DNA unavailability). Unfortunately the loss to follow-up of these patients did not allow us to perform any biochemical test to evaluate the *GAA* activity.

Discussion

We analyzed *GAA* together with all other genes included in the MotorPlex (15, 16) in 504 genetically undiagnosed patients who presented a wide spectrum of clinical phenotypes, ranging from isolated hyperCKemia to mild or severe muscular impairment, and a variable age of onset and disease progression (16). Two-hundred-seventy-five patients (in 259 families), presenting with a limb girdle muscular dystrophy (LGMD) and/or an isolated hyperCKemia, constituted a risk group for LOPD. Within this subgroup, we identified ten patients in nine families carrying *GAA* mutations consistent with a diagnosis of LOPD. Seven affected relatives were subsequently identified by segregation analyses in these families. This corresponds to a prevalence of LOPD of 3.47% (9/259) in the undiagnosed patients with adult onset proximal weakness or hyperCKemia. As expected, no bi-allelic causative *GAA* variants were identified among patients with other phenotypes such as, congenital myopathies, congenital dystrophies, distal myopathies, etc. Screening projects for Pompe disease by using DBS, in cohorts with similar phenotypes have been performed previously, achieving a similar results (9, 28-30), the only exception being Finland where Pompe disease is extremely rare (31) due to

lack of endemic founder mutations. Several factors have hampered an early diagnosis in all the reported cases. First, muscle biopsy showed not specific myopathic aspects in most cases. Second, the loss to follow-up of the patients for many years excluded an early detection of respiratory symptoms critical to raise the clinical suspicion of LOPD. Third, in most patients, the clinical presentation including atypical signs, e.g. dysphagia in patient III, pseudohypertrophy in patient VII or calf hypertrophy in patient VIII, was probably misleading. In patient I, a previous western blot analysis had showed a reduction of calpain 3 (*CAPN3*), and Sanger sequencing of *CAPN3* only revealed a heterozygous causative missense variant. At that time, the molecular findings may suggest the presence of a second elusive mutation, corroborating the preliminary diagnosis of LGMD2A. However, this patient was included in the study, because this second variant was truly absent from mRNA sequencing. This confirms that any genetic report should be very cautious in similar cases. Similarly, reduced staining for dystrophin in patient VIII suggested Becker dystrophy.

On the other hand, currently NGS-based strategies are largely adopted to study genetically heterogeneous conditions, including muscle diseases (14). Recent NGS data prove that 20-30% of myopathic patients carry causative mutations in genes typically not associated with the observed phenotype (16, 32-34). Many studies (32-37) identified mutations in genes responsible for LOPD and other metabolic myopathies in patients with a wide range of phenotypes (Table 2). At the same time, a well-known homozygous mutation in *ANO5*, responsible for a wide spectrum of disorders described under the umbrella term “anoctaminopathy” (38, 39), was identified in a patient suspected of having glycogen storage disease because of the presence of glycogen containing vacuoles on muscle biopsy (40).

The decreasing cost and the technological improvements will make NGS approaches an effective first tier screening method in the near future (41, 42). Given the large heterogeneity of neuromuscular disorders and the increasing number of associated genes, Mendeliome or whole exome sequencing are

advisable. However, the genetic analysis has to be included within a standardized diagnostic algorithm comprising exhaustive clinical, histological and imaging tests which are essential for a proper interpretation of molecular findings. Consequently, biochemical assays, including DBS, and protein studies will remain essential for the interpretation and validation of genetic results (34). Above all, tests for acid alpha-glucosidase activity are still the gold standard tests when clinicians suspect a Pompe disease in a patient. A smart, combined use of these tests and NGS will allow a rapid diagnosis and, thereby, an early initiation of available treatments.

Acknowledgements

We are grateful to Manuela Dionisi, Francesco Musacchia, Margherita Mutarelli and the Telethon Institute of Genetics and Medicine (TIGEM)-NGS facility for the NGS analyses and to Anna Cuomo and Rosalba Erpice for the Sanger sequence analyses. We thank Jonathan Cole for linguistic editing of the manuscript. We also thank the Italian Network of Congenital Myopathies, the Italian Network of Limb-Girdle Muscular Dystrophies, the Naples Human Mutation Gene Biobank (NHMGB), the Bank of muscle tissue, peripheral nerve, DNA and cell culture, and the Bank of Cells, tissues and DNA, members of the Telethon Network of Genetic Biobanks and of Eurobiobank, for providing us with specimens.

Funding

This study was supported by Telethon Foundation (Italy), Telethon-UILDM (Unione Italiana Lotta alla Distrofia Muscolare), Association Française contre les Myopathies and Orion Research Foundation. The funders had no role in the study design, data collection and analysis, decision to publish, or preparation of the manuscript.

References

1. Hers HG. alpha-Glucosidase deficiency in generalized glycogenstorage disease (Pompe's disease). *Biochem J.* 1963;86:11-6.
2. Toscano A, Barca E, Musumeci O. Update on diagnostics of metabolic myopathies. *Curr Opin Neurol.* 2017;30(5):553-62.
3. Kishnani PS, Hwu WL, Mandel H, Nicolino M, Yong F, Corzo D, et al. A retrospective, multinational, multicenter study on the natural history of infantile-onset Pompe disease. *J Pediatr.* 2006;148(5):671-6.
4. Angelini C, Engel AG. Comparative study of acid maltase deficiency. Biochemical differences between infantile, childhood, and adult types. *Arch Neurol.* 1972;26(4):344-9.
5. Laforet P, Nicolino M, Eymard PB, Puech JP, Caillaud C, Poenaru L, et al. Juvenile and adult-onset acid maltase deficiency in France: genotype-phenotype correlation. *Neurology.* 2000;55(8):1122-8.
6. Toscano A, Montagnese F, Musumeci O. Early is better? A new algorithm for early diagnosis in late onset Pompe disease (LOPD). *Acta Myol.* 2013;32(2):78-81.
7. Tsuburaya RS, Monma K, Oya Y, Nakayama T, Fukuda T, Sugie H, et al. Acid phosphatase-positive globular inclusions is a good diagnostic marker for two patients with adult-onset Pompe disease lacking disease specific pathology. *Neuromuscul Disord.* 2012;22(5):389-93.
8. Angelini C. Spectrum of metabolic myopathies. *Biochim Biophys Acta.* 2015;1852(4):615-21.
9. Musumeci O, la Marca G, Spada M, Mondello S, Danesino C, Comi GP, et al. LOPED study: looking for an early diagnosis in a late-onset Pompe disease high-risk population. *J Neurol Neurosurg Psychiatry.* 2016;87(1):5-11.
10. Vissing J, Lukacs Z, Straub V. Diagnosis of Pompe disease: muscle biopsy vs blood-based assays. *JAMA Neurol.* 2013;70(7):923-7.
11. van der Ploeg AT, Kruijshaar ME, Toscano A, Laforet P, Angelini C, Lachmann RH, et al. European consensus for starting and stopping enzyme replacement therapy in adult patients with Pompe disease: a 10-year experience. *Eur J Neurol.* 2017;24(6):768-e31.
12. Chien YH, Hwu WL, Lee NC. Pompe disease: early diagnosis and early treatment make a difference. *Pediatr Neonatol.* 2013;54(4):219-27.
13. Durmaz AA, Karaca E, Demkow U, Toruner G, Schoumans J, Cogulu O. Evolution of genetic techniques: past, present, and beyond. *Biomed Res Int.* 2015;2015:461524.
14. Nigro V, Savarese M. Next-generation sequencing approaches for the diagnosis of skeletal muscle disorders. *Curr Opin Neurol.* 2016;29(5):621-7.
15. Mamanova L, Coffey AJ, Scott CE, Kozarewa I, Turner EH, Kumar A, et al. Target-enrichment strategies for next-generation sequencing. *Nat Methods.* 2010;7(2):111-8.
16. Savarese M, Di Fruscio G, Torella A, Fiorillo C, Magri F, Fanin M, et al. The genetic basis of undiagnosed muscular dystrophies and myopathies: Results from 504 patients. *Neurology.* 2016;87(1):71-6.
17. Savarese M, Di Fruscio G, Mutarelli M, Torella A, Magri F, Santorelli FM, et al. MotorPlex provides accurate variant detection across large muscle genes both in single myopathic patients and in pools of DNA samples. *Acta Neuropathol Commun.* 2014;2:100.
18. Mutarelli M, Marwah V, Rispoli R, Carrella D, Dharmalingam G, Oliva G, et al. A community-based resource for automatic exome variant-calling and annotation in Mendelian disorders. *BMC Genomics.* 2014;15 Suppl 3:S5.
19. Spada M, Porta F, Vercelli L, Pagliardini V, Chiado-Piat L, Boffi P, et al. Screening for later-onset Pompe's disease in patients with paucisymptomatic hyperCKemia. *Mol Genet Metab.* 2013;109(2):171-3.
20. Piluso G, Dionisi M, Del Vecchio Blanco F, Torella A, Aurino S, Savarese M, et al. Motor chip: a comparative genomic hybridization microarray for copy-number mutations in 245 neuromuscular disorders. *Clin Chem.* 2011;57(11):1584-96.

21. Angelini C, Savarese M, Fanin M, Nigro V. Next generation sequencing detection of late onset Pompe disease. *Muscle Nerve*. 2016;53(6):981-3.
22. Boerkoel CF, Exelbert R, Nicastrì C, Nichols RC, Miller FW, Plotz PH, et al. Leaky splicing mutation in the acid maltase gene is associated with delayed onset of glycogenosis type II. *Am J Hum Genet*. 1995;56(4):887-97.
23. Fernandez-Hojas R, Huie ML, Navarro C, Dominguez C, Roig M, Lopez-Coronas D, et al. Identification of six novel mutations in the acid alpha-glucosidase gene in three Spanish patients with infantile onset glycogen storage disease type II (Pompe disease). *Neuromuscul Disord*. 2002;12(2):159-66.
24. Pittis MG, Donnarumma M, Montalvo AL, Dominissini S, Kroos M, Rosano C, et al. Molecular and functional characterization of eight novel GAA mutations in Italian infants with Pompe disease. *Hum Mutat*. 2008;29(6):E27-36.
25. Hermans MM, Kroos MA, de Graaff E, Oostra BA, Reuser AJ. Two mutations affecting the transport and maturation of lysosomal alpha-glucosidase in an adult case of glycogen storage disease type II. *Hum Mutat*. 1993;2(4):268-73.
26. Beesley CE, Child AH, Yacoub MH. The identification of five novel mutations in the lysosomal acid α -(1-4) glucosidase gene from patients with glycogen storage disease type II. *Mutations in brief no. 134*. Online. *Hum Mutat*. 1998;11(5):413.
27. Pittis MG, Montalvo AL, Miocic S, Martini C, Deganuto M, Candusso M, et al. Identification of four novel mutations in the alpha glucosidase gene in five Italian patients with infantile onset glycogen storage disease type II. *Am J Med Genet A*. 2003;121A(3):225-30.
28. Lukacs Z, Nieves Cobos P, Wenninger S, Willis TA, Guglieri M, Roberts M, et al. Prevalence of Pompe disease in 3,076 patients with hyperCKemia and limb-girdle muscular weakness. *Neurology*. 2016;87(3):295-8.
29. Almeida V, Conceicao I, Fineza I, Coelho T, Silveira F, Santos M, et al. Screening for Pompe disease in a Portuguese high risk population. *Neuromuscul Disord*. 2017;27(8):777-81.
30. Preisler N, Lukacs Z, Vinge L, Madsen KL, Husu E, Hansen RS, et al. Late-onset Pompe disease is prevalent in unclassified limb-girdle muscular dystrophies. *Mol Genet Metab*. 2013;110(3):287-9.
31. Palmio J, Auranen M, Kiuru-Enari S, Lofberg M, Bodamer O, Udd B. Screening for late-onset Pompe disease in Finland. *Neuromuscul Disord*. 2014;24(11):982-5.
32. Ghaoui R, Cooper ST, Lek M, Jones K, Corbett A, Reddel SW, et al. Use of Whole-Exome Sequencing for Diagnosis of Limb-Girdle Muscular Dystrophy: Outcomes and Lessons Learned. *JAMA Neurol*. 2015;72(12):1424-32.
33. Todd EJ, Yau KS, Ong R, Slee J, McGillivray G, Barnett CP, et al. Next generation sequencing in a large cohort of patients presenting with neuromuscular disease before or at birth. *Orphanet J Rare Dis*. 2015;10:148.
34. Levesque S, Auray-Blais C, Gravel E, Boutin M, Dempsey-Nunez L, Jacques PE, et al. Diagnosis of late-onset Pompe disease and other muscle disorders by next-generation sequencing. *Orphanet J Rare Dis*. 2016;11:8.
35. Kuhn M, Glaser D, Joshi PR, Zierz S, Wenninger S, Schoser B, et al. Utility of a next-generation sequencing-based gene panel investigation in German patients with genetically unclassified limb-girdle muscular dystrophy. *J Neurol*. 2016;263(4):743-50.
36. Reddy HM, Cho KA, Lek M, Estrella E, Valkanas E, Jones MD, et al. The sensitivity of exome sequencing in identifying pathogenic mutations for LGMD in the United States. *J Hum Genet*. 2017;62(2):243-52.
37. Johnson K, Topf A, Bertoli M, Phillips L, Claeys KG, Stojanovic VR, et al. Identification of GAA variants through whole exome sequencing targeted to a cohort of 606 patients with unexplained limb-girdle muscle weakness. *Orphanet J Rare Dis*. 2017;12(1):173.
38. Savarese M, Di Fruscio G, Tasca G, Ruggiero L, Janssens S, De Bleecker J, et al. Next generation sequencing on patients with LGMD and nonspecific myopathies: Findings associated with ANO5 mutations. *Neuromuscul Disord*. 2015;25(7):533-41.
39. Nigro V, Savarese M. Genetic basis of limb-girdle muscular dystrophies: the 2014 update. *Acta Myol*. 2014;33(1):1-12.

40. Vega AI, Medrano C, Navarrete R, Desviat LR, Merinero B, Rodriguez-Pombo P, et al. Molecular diagnosis of glycogen storage disease and disorders with overlapping clinical symptoms by massive parallel sequencing. *Genet Med*. 2016.
41. Gonzaga-Jauregui C, Lupski JR, Gibbs RA. Human genome sequencing in health and disease. *Annu Rev Med*. 2012;63:35-61.
42. Alyass A, Turcotte M, Meyre D. From big data analysis to personalized medicine for all: challenges and opportunities. *BMC Med Genomics*. 2015;8:33.

Accepted Manuscript

Table 1 - Patients with late-onset Pompe disease

Case	Onset	Age at diagnosis (yrs)	Symptoms at onset			Last assessment					Genotype (NG_009822.1 or NM_000152.3)	
			Limb weak.	Resp.	Other	6MWT (mt)	Plasma CK	FVC seated ml (%N)	Histology	GAA activity (pmol/min/mg)	1st Allele	2nd Allele
I	early adul.	49	prox.	no	fatigability	n.a.	5-10X	n.a.	myopathic	lymphocytes:14.2	c.784G>A;p.E262K (ref. 23)	
II*	adul.	71	prox.	no	myalgia	40	5-10X	850 (22%)	myopathic	DBS:0	c.1564C>G;p.P522A (ref. 27)	
III	adul.	63	prox. and dist.	no	fatigability, dysphagia	n.a.	2.5-5X	n.a.	myopathic	muscle: 11.7	c.1927G>A;p.G643R (ref. 25)	
IV,1	early adul.	40	prox.	yes	exercise intolerance	n.a.	2.5-5X	n.a.	vacuoles	n.a.	c.1124G>T;p.R375L (ref. 24)	c.-32-13T>G (ref. 18)
IV,2	early adul.	47	prox.	yes		n.a.	2.5-5X	n.a.	n.a.	n.a.		
IV,3	early adul.	50	not observed	no		n.a.	2.5-5X	n.a.	n.a.	n.a.		
IV,4	early adul.	45	prox.	no		n.a.	2.5-5X	n.a.	vacuoles	n.a.		
V,1	adol.	42	prox.	no	fatigability, myalgia	135	5-10X	950 (20%)	vacuoles	DBS: 0.20	c.1124G>T;p.R375L (ref. 24)	
V,2	adul.	33	prox.	no	fatigability	566	5-10X	3000 (90%)	n.a.	DBS: 0.20		
V,3	child.	45	prox.	no		n.a.	2.5-5X	n.a.	n.a.	DBS: 0.08		
VI,1	early adul.	63	prox. and axial	yes	fatigability, myalgia	n.a.	normal	1520 (38%)	n.a.	DBS: 0.24	c.2237G>A;p.W746* (ref. 26)	
VI,2	adul.	61	prox.	yes	fatigability	418	2.5-5X	2040 (46%)	myopathic	DBS: 0.22		

VI,3	adul.	64	prox.	yes		n.a.	2.5-5X	1550 (48%)	n.a.	DBS: 0.16	
VII	adol.	33	prox. and dist.	no	cramps	n.a.	2.5-5X	5260 (112%)	vacuoles	DBS: 0.20	c.784G>A;p.E262K (ref. 23)
VIII	early adul.	56	prox.	no	fatigability, myalgia	385	2.5-5X	2480 (75%)	myopathic	DBS: 0.13	c.G989A;p.W330* (ref. 27)
IX	early adul.	n.a.	prox.	yes	fatigability, cardiac involvement	WCB	n.a.	n.a.	n.a.	n.a.	c.1124G>T;p.R375L (ref. 24)

yrs= years; Resp.=respiratory; 6MWT= 6 minutes walking test; N=normal; adult.=adulthood; child.=childhood; adol.=adolescence; prox.=proximal; dist.=distal; n.a.=not available; DBS=dried blood spot; CK=creatine kinase; FVC=forced vital capacity; WCB=Wheel-chair-bound

*Patient II has been described in full elsewhere (ref. 21)

Table 2 - Broadening the spectrum of clinical phenotypes associated with metabolic myopathies by next generation sequencing.

Reference	Genetic approach	Cohort	Results	Atypical elements
Ghaoui et al. (ref.30)	WES	LGMD (n=60)	1 GAA*	n.a.
			1 CPT2	fixed weakness
			1 PYGM	fixed weakness
Todd et al. (ref. 31)	WES	LGMD (n=38)	1 GBE	fetal akinesia and multiple pterygium syndrome
Lévesque et al. (ref. 32)	Targeted resequencing	Muscle Disorders (n=34)	1 GAA	long lasting history of gait disturbances
Kuhn et al. (ref. 33)	Targeted resequencing	LGMD (n=58)	1 GBE	minimal non-lysosomal glycogen storage without any evidence of polyglucosan bodies
Reddy et al. (ref. 34)	WES	LGMD (n=55)	1 GAA	n.a.
			1 VCP	
Johnson et al. (ref.35)	WES	LGMD and/or hyperCKemia (n=606)	8 GAA	n.a.

n.a.= not available; WES= whole exome sequencing

* LOPD patient was identified in a pre-NGS screening.